[1] |
江苏新医学院.中药大辞典[M].上海:上海科学技术出版社,1986:2111.
|
[2] |
孙艳怡.自拟地龙散配合火疗疗法治疗血瘀型腰椎间盘突出症临床疗效观察[J].内蒙古中医药,2019,38(2):69-70.
|
[3] |
刘巧,毕启瑞,谭宁华.地龙蛋白多肽类成分的研究进展[J].中草药,2019,50(1):252-261.
|
[4] |
李娟,吴永胜,邱时秀,等.蚓激酶的最新研究进展[J].四川畜牧兽医,2017,44(8):34-35.
|
[5] |
王佳茜,王少平,刘万卉.地龙抗血栓肽分离研究[J].天津药学,2019,31(3):1-4.
|
[6] |
涂清波,苏鹏亮,林颖,等.蚓激酶的提取工艺改进研究[J].天津中医药,2018,35(1):65-67.
|
[7] |
Pan Y,Wang X,Yin Z.Synthesis and evaluation of cationic polymeric micelles as carriers of lumbrokinase for targeted thrombolysis[J].Asian J Pharm Sci,2019,14(2):144-153.
|
[8] |
王婷.巴曲酶序贯蚓激酶治疗脑梗死的效果[J].临床医学研究与实践,2019,4(3):44-46.
|
[9] |
许秀秀.重组单环刺螠纤溶酶对大鼠急性心肌缺血的保护作用[J].中国现代应用药学,2019,36(8):910-915.
|
[10] |
梅斯医学.盘点2016 脑卒中重要指南共识回顾[J].心脑血管病防治,2017,17(1):1-2.
|
[11] |
吴毅.脑卒中康复治疗基础与临床研究的新进展[J].中国康复医学杂志,2008,1(7):587-588.
|
[12] |
饶明俐,林世和.脑血管疾病[M].2版.北京:人民卫生出版社,2012:33.
|
[13] |
GBD 2016 Mortality Collaborators.Global,regional,and national under-5 mortality,adult mortality,age-specific mortality,and life expectancy,1970-2016:a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet,2017,390(10100):1084-1150.
|
[14] |
金莲,陶俐.蚓激酶治疗脑梗死的临床效果观察[J].中国生化药物杂志,2016,36(2):160-161.
|
[15] |
Wang XM,Fan SC,Chen Y,et al.Earthworm protease in anti-thrombosis and anti-fibrosis[J].Biochim Biophys Acta Gen Subj,2019,1863(2):379-383.
|
[16] |
许超千.蚓激酶注射液抗血栓作用机制的研究[D].哈尔滨:哈尔滨医科大学,2005.
|
[17] |
徐晓夏.蚓激酶在血栓溶解和形成过程中的作用研究[D].呼和浩特:内蒙古医科大学,2015.
|
[18] |
中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
|
[19] |
彭斌,吴波.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
|
[20] |
黄瑛.蚓激酶及其在心血管疾病中的研究进展[J].中国医药指南,2012,10(2):64-65.
|
[21] |
孟森.蚓激酶联合奥扎格雷钠治疗急性脑梗死临床疗效分析[J].中国实用医药,2015,10(22):135-136.
|
[22] |
高志强,柏燕燕,孔玉,等.氯吡格雷联合蚓激酶治疗对急性脑梗死患者血浆D-二聚体、血小板聚集和纤维蛋白原的影响[J].江苏医药,2014,40(14):1707-1708.
|
[23] |
金莲,陶俐.蚓激酶治疗脑梗死的临床效果观察[J].中国生化药物杂志,2016,36(2):160-161.
|
[24] |
陈宇飞.蚓激酶联合奥扎格雷钠治疗急性脑梗死临床疗效分析[J].天津药学,2019,31(2):44-46.
|
[25] |
王陇德,王金环,彭斌,等.《中国脑卒中防治报告2016》概要[J].中国脑血管病杂志,2017,14(4):217-224.
|
[26] |
左懿.蚓激酶联合阿司匹林在脑梗死二级预防中的应用效果[J].中国实用神经疾病杂志,2015,18(1):119-120.
|
[27] |
段红利,刘骅.蚓激酶联合阿司匹林在脑梗死二级预防中的疗效及安全性观察[J].首都食品与医药,2011,18(16):43-44.
|
[28] |
张春华.蚓激酶对动脉粥样硬化性脑梗死二级预防作用探讨[J].中风与神经疾病杂志,2010,27(11):1005-1006.
|
[29] |
Antithrombotic Trialists′ (ATT) Collaboration,Baigent C,Blackwell L,et al.Aspirin in the primary and secondary prevention of vascular disease:collaborative meta-analysis of individual participant data from randomised trials[J].Lancet,2009,373(9678):1849-1860.
|
[30] |
Gaziano JM,Brotons C,Coppolecchia R,et al.Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE):a randomised,double-blind,placebo-controlled trial[J].Lancet,2018,392(10152):1036-1046.
|
[31] |
Shinohara Y,Katayama Y,Uchiyama S,et al.Cilostazol for prevention of secondary stroke (CSPS 2):an aspirin-controlled,double-blind,randomised non-inferiority trial[J].Lancet Neurol,2010,9(10):959-968.
|
[32] |
Johnston SC,Easton JD,Farrant M,et al.Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J].N Engl J Med,2018,379(3):215-225.
|
[33] |
周霞.高龄患者服用小剂量肠溶阿司匹林的不良反应和有效性分析[J].中国医药指南,2015,13(11):72-73.
|
[34] |
仲伟芹.高龄患者长期口服阿司匹林主要不良反应的回顾性研究[D].长春:吉林大学,2015.
|
[35] |
Kernan WN,Ovbiagele B,Black HR,et al.Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2014,45(7):2160-2236.
|
[36] |
ASCEND Study Collaborative Group,Bowman L,Mafham M,et al.Effects of aspirin for primary prevention in persons with diabetes mellitus[J].N Engl J Med,2018,379(16):1529-1539.
|
[37] |
Ozben S,Ozben B,Tanrikulu AM,et al.Aspirin resistance in patients with acute ischemic stroke[J].J Neurol,2011,258(11):1979-1986.
|
[38] |
王建新.“神药”阿司匹林的困惑[N].医药经济报,2018-10-29(008).
|
[39] |
高娇娇,李永秋.阿托伐他汀或蚓激酶联合阿司匹林治疗缺血性脑血管病的疗效观察[J].临床合理用药,2015,8(7):50-51.
|
[40] |
牟梓樟,孔繁呈,侯立刚.舒血宁注射液联合蚓激酶治疗脑梗死的临床研究[J].现代药物与临床,2018,33(2):238-241.
|
[41] |
陈汉文,何苑英,莫美华,等.蚓激酶单用与联合小剂量尿激酶治疗急性进展性脑梗死对比观察[J].中国医学创新,2017,14(11):17-20.
|